Expert Roundtable, Michael Seiden, MD, PhD

Editor's Notes

• #30: Nanotechnologies will dramatically change the field of oncology and the genomics will radically change pathology. This a prototype of device of that not only can count but capture circulating tumor cells. These cells can be counted, evaluated by immunohistochemistry, fish, or now sequenced. Indeed, there is now early technology for doing sequencing on circulating tumor cells or cell free DNA. Soon it will be possible to gain significant omic information on tumors without invasive biopsies. The old age of “when tumor is the rumor tissue is the issue” will go away in the next decade!
• #31: Nanotechnologies will dramatically change the field of oncology and the genomics will radically change pathology. This a prototype of device of that not only can count but capture circulating tumor cells. These cells can be counted, evaluated by immunohistochemistry, fish, or now sequenced. Indeed, there is now early technology for doing sequencing on circulating tumor cells or cell free DNA. Soon it will be possible to gain significant omic information on tumors without invasive biopsies. The old age of “when tumor is the rumor tissue is the issue” will go away in the next decade!
• #33: Figure 1 Clinical Responses to Pembrolizumab Treatment. The biochemical responses to pembrolizumab treatment are shown in Panel A. Serum levels of protein biomarkers were measured at the start of each treatment cycle, and the values represent percentage changes from baseline. Each line represents one patient; patients were included if their baseline tumor marker values were higher than the upper limit of normal. CA-125 was used as the biomarker for one patient with endometrial cancer, CA19-9 was used for one patient with cholangiocarcinoma and one patient with ampullary cancer, and carcinoembryonic antigen (CEA) was used for all other patients. Radiographic responses to treatment with pembrolizumab, evaluated on the basis of Response Evaluation Criteria in Solid Tumors (RECIST), are shown in Panel B. Tumor responses were measured at regular intervals, and the values shown are the largest percentage change in the sum of longest diameters from the baseline measurements of each measurable tumor. Each bar represents one patient.
• #34: Figure 1 Clinical Responses to Pembrolizumab Treatment. The biochemical responses to pembrolizumab treatment are shown in Panel A. Serum levels of protein biomarkers were measured at the start of each treatment cycle, and the values represent percentage changes from baseline. Each line represents one patient; patients were included if their baseline tumor marker values were higher than the upper limit of normal. CA-125 was used as the biomarker for one patient with endometrial cancer, CA19-9 was used for one patient with cholangiocarcinoma and one patient with ampullary cancer, and carcinoembryonic antigen (CEA) was used for all other patients. Radiographic responses to treatment with pembrolizumab, evaluated on the basis of Response Evaluation Criteria in Solid Tumors (RECIST), are shown in Panel B. Tumor responses were measured at regular intervals, and the values shown are the largest percentage change in the sum of longest diameters from the baseline measurements of each measurable tumor. Each bar represents one patient.